Publications by authors named "L V Kalman"
Article Synopsis
- - The DPYD gene is crucial for encoding dihydropyrimidine dehydrogenase (DPD), which helps metabolize drugs like 5-fluorouracil used in cancer treatment; reduced DPD activity can lead to severe side effects in patients.
- - To improve pharmacogenetic testing for DPYD, a collaboration among various organizations created and distributed 33 characterized DNA samples from Coriell cell lines to different laboratories for testing.
- - These samples allowed the identification of 33 distinct DPYD variants and are intended to enhance quality assurance and control in clinical testing for better patient safety in cancer treatment.
Article Synopsis
- The Association for Molecular Pathology's Pharmacogenomics Working Group aims to establish key attributes and a standard set of genetic variants for clinical pharmacogenetic testing.
- The document outlines two tiers of recommended genetic variants, which will guide clinical laboratories in creating pharmacogenomics assays.
- Focused on dihydropyrimidine dehydrogenase (DPYD) testing, the recommendations encourage standardization while serving as a flexible reference rather than strict rules.
Introduction: The 2023 Australian guideline for assessing and managing cardiovascular disease risk provides updated evidence-based recommendations for the clinical assessment and management of cardiovascular disease (CVD) risk for primary prevention. It includes the new Australian CVD risk calculator (Aus CVD Risk Calculator), based on an equation developed from a large New Zealand cohort study, customised and recalibrated for the Australian population. The new guideline replaces the 2012 guideline that recommended CVD risk assessment using the Framingham risk equation.
View Article and Find Full Text PDFArticle Synopsis
- Primary graft dysfunction (PGD) is a significant cause of complications and mortality after lung transplants, and predicting its risk can help in donor selection and patient care planning.
- Researchers created a predictive model using data from a study conducted between 2012 and 2018, which evaluated various clinical factors to forecast the risk of PGD and developed a user-friendly interface for real-time assessments.
- The model incorporates numerous variables like distance from the donor hospital, recipient characteristics, and donor factors, showing a net benefit for decision-making in predicting PGD risk across different levels, making it a valuable tool for transplantation processes.
Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. Prior studies implicated proxy-defined donor smoking as a risk factor for PGD and mortality. We aimed to more accurately assess the impact of donor smoke exposure on PGD and mortality using quantitative smoke exposure biomarkers.
View Article and Find Full Text PDF